Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Solid Tumors × ridaforolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 2 Solid Tumors 1 Recurrence 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Lymphoma 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Advanced Cancers 1

Interventions

Gemcitabine 5 Paclitaxel 3 Nivolumab 3 cobimetinib 2 atezolizumab 2 Ramucirumab 2 Carboplatin 2 zansecimab 1 tocilizumab 1 tivozanib 1 tislelizumab 1 temsirolimus 1 ridaforolimus 1 plocabulin 1 pevonedistat 1 pembrolizumab 1 pamiparib 1 obinutuzumab 1 necitumumab 1 liposomal doxorubicin 1 lenvatinib 1 glasdegib 1 futuximab 1 demplatin pegraglumer 1 birinapant 1 adavosertib 1 Temozolomide 1 TAK-981 1 Sunitinib 1 Specimen Handling 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01431534 2019-03-01

MK-8669-056

Merck Sharp & Dohme LLC

Phase 1 Terminated

20 enrolled 10 charts

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡